VEGF and prostatic cancer: A systematic review

European Journal of Cancer Prevention

Volumn 19, Issue 5, 2010, Pages 385-392

  Botelho, Francisco ^a,b   Pina, Francisco ^a   Lunet, Nuno ^b  

^a Hospital de S Joao   (Brazil)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

detection; prostate cancer; systematic review; tumour marker; vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN; TUMOR MARKER; VASCULOTROPIN A;

BENIGN TUMOR; DIFFERENTIAL DIAGNOSIS; HIGH RISK PATIENT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SYSTEMATIC REVIEW; BIOPSY; BLOOD; MALE; PATHOLOGY; PROSTATE; PROSTATE TUMOR; RISK;

BIOPSY; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RISK; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77955278698     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32833b48e1     Document Type: Review

References (52)

1. Al-Moundhri MS, Al-Shukaili A, Al-Nabhani M, Al-Bahrani B, Burney IA, Rizivi A, et al. (2008). Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. World J Gastroenterol 14:3879-3883.
2. Alvaro D, Macarri G, Mancino MG, Marzioni M, Bragazzi M, Onori P, et al. (2007). Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Ann Intern Med 147:451-459.
3. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY (2003). Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 88:1721-1726.
4. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E,Walters C, et al. (1998). Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77:956-964.
5. Botelho F, Pina F, Figueiredo G, Cruz F, Lunet N (2010). Vascular endothelial growth factor (VEGF) and prostatic pathology. International Braz J Urol (in press).
6. Caine GJ, Lip GY, Stonelake PS, Ryan P, Blann AD (2004a). Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 92:185-190.
7. Caine GJ, Lip GY, Blann AD (2004b). Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Ann Med 36:273-277.
8. Chang YT, Chang MC,Wei SC, Tien YW, Hsu C, Liang PC, et al. (2008). Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas 37:145-150.
9. Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR (1999). Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54:523-527.
10. Duranyildiz D, Camlica H, Soydinc HO, Derin D, Yasasever V (2009). Serum levels of angiogenic factors in early breast cancer remain close to normal. Breast 18:26-29. [Epub 2008 November 8]
11. Dvorak HF (2002). Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368-4380.
12. El-Houseini ME, Abdel-Azim SA, El-Desouky GI, Abdel-Hady S, El-Hamad MF, Kamel AM (2004). Clinical significance of vascular endothelial growth factor (VEGF) in sera of patients with pediatric malignancies. J Egypt Natl Canc Inst 16:57-61.
13. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, et al. (1997). Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 157:2329-2333.
14. Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995). Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70.
15. Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Niknejad K, et al. (1995). Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 55:4140-4145.
16. Gadducci A, Tana R, Cosio S, Genazzani AR (2008). The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol 66:10-20. [Epub 2007 October 26]
17. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI (2000). Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 6:3147-3152.
18. George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, et al. (2004). Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology 63:327-332.
19. Hammerer PG, Kattan MW, Mottet N, Prayer-Galetti T (2006). Using prostatespecificantigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer. BJU Int 98:11-19.
20. Jacobsen J, Grankvist K, Rasmuson T, Ljungberg B (2002). Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma. Eur J Cancer Prev 11:245-252.
21. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, et al. (2009). The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 8:2496-2508. [Epub 9 September 15]
22. Jemal A, Siegel R,Ward E, Hao Y, Xu J, Murray T, et al. (2008). Cancer statistics,2008. CA Cancer J Clin 58:71-96.
23. Jin Y, Xiong X, Su Y, Hu J, Tao X (2009). Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer and its relation to the micrometastasis in peripheral blood. J Huazhong Univ Sci Technolog Med Sci 29:462-465. [Epub 2009 August 7]
24. Joao Bugalho M, Madureira D, Espadinha C, Paula Font A, Sobrinho LG (2008). Serum vascular endothelial growth factor levels in patients with medullary thyroid carcinoma. Eur J Endocrinol 159:167-169. [Epub 2008 May 1]
25. Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Bicknell R, et al. (2000). Elevated serum vascular endothelial growth factor in patients with hormoneescaped prostate cancer. BJU Int 85:276-280.
26. Kumar H, Heer K, Lee PW, Duthie GS, MacDonald AW, Greenman J, et al. (1998). Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 4:1279-1285.
27. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, et al. (2000). Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 6:2295-2308.
28. Li YH, Shao JY, Li S, Zou BY, Huang HQ, Guan ZZ (2004). Clinical significance of quantitative analysis of serum VEGF, CD44 s, and MMP-3 protein in nasopharyngeal carcinoma. Ai Zheng 23:1060-1064.
29. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, et al. (1999). Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 282:1061-1066.
30. Margreiter M, Stangelberger A, Valimberti E, Herwig R, Djavan B (2008). Biomarkers for early prostate cancer detection. Minerva Urol Nefrol 60:51-60.
31. Nakanishi R, Oka N, Nakatsuji H, Koizumi T, Sakaki M, Takahashi M, et al. (2009). Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. Urol Int 83:98-106. [Epub 2009 July 27]
32. Nicholson B, Theodorescu D (2004). Angiogenesis and prostate cancer tumor growth. J Cell Biochem 91:125-150.
33. Pepe P, Panella P, D'Arrigo L, Savoca F, Pennisi M, Aragona F (2006). Should men with serum prostate-specific antigen r4ng/ml and normal digital rectal examination undergo a prostate biopsy? A literature review. Oncology 70:81-89.
34. Peyromaure M, Goulvestre C, Fulla Y, Grabar S, Debre B, Dinh-Xuan AT (2005). Serum levels of vascular endothelial growth factor in patients undergoing prostate biopsy for suspicion of prostate cancer. Urology 66:687-691.
35. Poreba M, Jazwiec B, Kuliczkowski K, Poreba R (2005). Circulating endothelial cells, endothelial precursors, VEGF and bFGF concentrations in patients with acute leukemias, lymphomas and myelomas. Pol Arch Med Wewn 113:27-34.
36. Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM (2005). Case-control and two-gate designs in diagnostic accuracy studies. Clin Chem 51:1335-1341. [Epub 2005 June 16]
37. Rutjes AW, Reitsma JB, Di Nisio M, Smidt N, van Rijn JC, Bossuyt PM (2006). Evidence of bias and variation in diagnostic accuracy studies. Can Med Assoc J 174:469-476.
38. Salgado R, Vermeulen PB, Van Marck E, Benoy I, Dirix L (2000). Correspondence re: George M.L. et al. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 6:3147-3152. (Clin Cancer Res 2001; 7:1481-1483).
39. Salgado R, Benoy I, Bogers J, Weytjens R, Vermeulen P, Dirix L, et al. (2001). Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis 4:37-43.
40. Schenk-Braat EA, Bangma CH (2006). The search for better markers for prostate cancer than prostate-specific antigen. Ned Tijdschr Geneeskd 150:1286-1290.
41. Schips L, Dalpiaz O, Lipsky K, Langner C, Rehak P, Puerstner P, et al. (2007). Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol 51:168-173. Discussion 74. [Epub 2006 July 5]
42. Schroder FH (2009). Review of diagnostic markers for prostate cancer. Recent Results Cancer Res 181:173-182.
43. Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM (2004). Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 22:1655-1663.
44. Shen JK, Dong LH, Qi H, Zhang GS (2005). Clinical significance of serum vascular endothelial growth factor and interleukin-6 in multiple myeloma. Zhong Nan Da Xue Xue Bao Yi Xue Ban 30:68-71.
45. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E (2008). Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase- 3 (MMP-3), and BCL-2 in malignant melanoma. Med Oncol 25:431-436. [Epub 2008 March 25]
46. Thompson IM, Ankerst DP (2007). Prostate-specific antigen in the early detection of prostate cancer. Can Med Assoc J 176:1853-1858.
47. Trapeznikova MF, Shibaeva AN, Ianshin AA, Urenkov SB, Mironova OS, Kazantseva IA, et al. (2004). Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. Urologiia 1:17-21.
48. Trapeznikova MF, Shibaev AN, Kazantseva IA, Mironova OS, Gurevich LE, Morozov AP, et al. (2005). Vascular endothelial growth factor in patients with prostate cancer and benign prostatic hyperplasia. Vestn Ross Akad Med Nauk 5:14-16.
49. Tseng CS, Lo HW, Chen PH, Chuang WL, Juan CC, Ker CG (2004). Clinical significance of plasma D-dimer levels and serum VEGF levels in patients with hepatocellular carcinoma. Hepatogastroenterology 51:1454-1458.
50. Walsh K, Sherwood RA, Dew TK, Mulvin D (1999). Angiogenic peptides in prostatic disease. BJU Int 84:1081-1083.
51. Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, et al. (1996). Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 2:821-826.
52. Yu XM, Lo CY, Lam AK, Lang BH, Leung P, Luk JM (2008). The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery 144:934-940. Discussion 40-41.